** Morningstar says it is upbeat on Australia's Telix Pharmaceuticals after co reported FY24 revenue ahead of its own and brokerage's forecasts
** "Telix is broadly tracking our expectations and we leave our constant-currency forecasts broadly unchanged," says brokerage
** Morningstar raises fair value estimate on stock by 6% to A$18, largely on stronger U.S. dollar
** Seven of eight analysts rate the stock "buy" or higher, one "hold"; their median PT is A$23.80 – LSEG data
** Stock has gained 1.5% YTD, as of last close
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。